
    
      Exploratory Endpoints:

      The association between the efficacy of the combination treatment and changes in CTC counts
      after administration of the treatment.

      Evaluating the correlation between programmed death ligand 1 (PD-L1) expression derived from
      circulating tumor cells (CTC) and tumor tissue cells, and the predictive role of CTC PD-L1
      expression in ED-SCLC.

      The compositional changes in the gut microbiota after administration of the treatment and its
      association with the efficacy of the combination treatment.
    
  